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ABSTRACT
Aims/Introduction: To determine the current clinical preferences of anti-vascular
endothelial growth factor (VEGF) treatment protocols for diabetic macular edema (DME) in
Japan.
Materials and Methods: This was a descriptive cross-sectional study. Answers to a
questionnaire consisting of 16 questions were obtained from 176 of 278 (63.3%) surveyed
ophthalmologists.
Results: The results showed that 81.2% preferred intravitreal injections of anti-VEGF anti-
bodies as the first-line therapy. The most important indicators for beginning anti-VEGF
therapy were: the best-corrected visual acuity in 44.3% and the retinal thickness in 30.7%.
In the loading phase, 53.4% preferred a single injection, and in the maintenance phase,
75.0% preferred the pro re nata regimen. Financial limitation (85.8%) was reported as the
most important difficulty in the treatment. For combination therapy with anti-VEGF treat-
ment, panretinal photocoagulation, focal photocoagulations and a sub-Tenon steroid injec-
tion were preferred. The contraindications for anti-VEGF therapy were: prior cerebral
infarction (72.7%). Regarding the use of both approved anti-VEGF agents in Japan, ranibi-
zumab and aflibercept, 39.8% doctors used them appropriately.
Conclusions: Our results present the current clinical preferences of anti-VEGF treatment
for DME in Japan. The best-corrected visual acuity and the retinal thickness are important
indicators to institute this therapy. The majority of the ophthalmologists use anti-VEGF
treatment as first-line therapy and prefer the 1 + pro re nata regimen.
INTRODUCTION
Diabetic retinopathy (DR) is a leading cause of blindness, and
it is present in over one-half of patients with diabetes mellitus
of >20 years duration1. Diabetic macular edema (DME) is the
most common cause of the vision reduction in eyes with DR2.
Various surgical and medical therapies have been used to treat
DME, and pharmacological therapies; for example, anti-vascular
endothelial growth factor (VEGF) antibodies, have become the
ﬁrst-line therapy for DME. VEGF has been shown to play a
major role in the progression of DME, and anti-VEGF agents;
for example, bevacizumab (AvastinTM; Genentech, San Fran-
cisco, CA, USA), ranibizumab (LucentisTM; Genentech) and
aﬂibercept (EyleaTM; Regeneron Pharmaceuticals, Tarrytown,
NY, USA) are commercialized anti-VEGF agents. The results of†Writing Committee of Japan-Clinical Retina Study group (J-CREST).
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many randomized clinical trials (RCTs) have found that treat-
ment with anti-VEGF agents led to a rapid improvement of
vision in eyes with DME. The results of RCTs have shown the
superiority of intravitreal anti-VEGF treatments over existing
macular focal/grid laser photocoagulations (PC) and intravitreal
triamcinolone acetonide (IVTA) injections3,4. Thus, anti-VEGF
treatment has become the ﬁrst-line therapy for DME. Even
though the results of these clinical trials are well known and
many ophthalmologists have changed their treatment regimen
for DME, it is difﬁcult to rely on the results of RCTs alone, as
they have limitations, such as the inclusion criteria, treatment
options and initial visual acuities. In addition, two of the anti-
VEGF agents, ranibizumab and aﬂibercept, have been approved
for DME with comparable prices. Different from other coun-
tries, sustained-release steroid agents and bevacizumab have not
been approved in Japan. There still exists some skepticism of
the results of the RCTs, as they were carried out with speciﬁc
populations and in specialized environments.
To overcome differences between the RCTs and the real-
world clinical practice, the need for “real-world evidence
(RWE)” has been advocated5. Different from the traditional
RCTs, RWE studies are population-based observational studies,
and are less prone to selection with referral biases, which can
identify gaps from the RCT results6. For example, the Aspirin
Dosing: A Patient-Centric Trial Assessing Beneﬁts and Long-
Term Effectiveness (ADAPTABLE) study is an ongoing repre-
sentative large RWE study with 20,000 participants assigned
two dose regimens (81 vs 325 mg) of aspirin to prevent heart
attacks and strokes7. However, because RWE can be used in
multiple research interventions at the levels of health systems,
practices and hospitals, appropriate analyses of large numbers
using cluster randomization is useful to strengthen the RWE
results8. In fact, there are many recent reports on DME treat-
ment based on RWE studies9–11.
As the ﬁrst step of translating the RWE results for DME
treatment, it is important to understand how physicians use
anti-VEGF agents in the real-world. For this, a questionnaire-
based survey of ophthalmologists about treatment protocols
was carried out in Canada and France12,13. The results of the
real-world treatment protocols on randomized patients are
required to establish general clinical protocols for the treatment
of DME in Japan.
Thus, the aim of the present study was to determine the cur-
rent clinical preferences and trends of anti-VEGF treatments
for eyes with DME in Japan. To accomplish this, we surveyed
176 ophthalmologists in Japan with a questionnaire.
METHODS
Study design
This was a descriptive cross-sectional study. A questionnaire
was sent to 278 ophthalmologists in Japan between March
2016 and June 2017. All ophthalmologists were treating DME
patients and were informed that their identity would be anony-
mous.
The protocol for this study was approved by the institu-
tional review board of Mie University Graduate School of
Table 1 | Demographics of respondents
Classification Question
I. General Matters
(I-1) Background (I-1-①) Practice years
(I-2) Changes in attitude (I-2-①) Anti-VEGF therapy changed your therapeutic strategies for DME treatment?
(I-2-②) Anti-VEGF is more effective than STTA?
(I-3) Management before and after Injection (I-3-①) How do you use topical antibiotics?
(I-3-②) When is the initial examination after injection?
II. Treatment Practice Pattern
(II-1) Initial DME Treatment (II-1-①) What kind of therapy is used as the initial therapy for DME (multiple choice)
(II-2) Anti-VEGF Treatment regimen (II-2-①) When did you decide to use anti-VEGF for DME for the first time?
(II-2-②) What is the most important assessment indicator for initial therapeutic intervention?
(II-2-③) How many anti-VEGF injections for DME do you perform? (loading phase)
(II-2-④) How do you treat anti-VEGF injections for DME after an effective loading phase?
(maintenance phase)
(II-2-⑤) Maximum number of anti-VEGF injections you perform before incorporating other therapy
(II-2-⑥) What is an important problem of anti-VEGF treatment for DME?
III. Alternative Therapy
(III-1) Combination Therapy (III-1-①) What kind of combination therapy with anti-VEGF treatment is
used for DME? (multiple choice)
(III-1-②) Which systemic disorder you pay attention with anti-VEGF treatment for DME?
(multiple choice)
(III-2) Alternative use of anti-VEGF agents (III-2-①) Do you use two approved anti-VEGF agents (ranibizumab and aflibercept) properly?
(III-2-②) On what basis do you distinguish them?
DME, diabetic macular edema; STTA, sub-Tenon triamcinolone acetonide injection; VEGF, vascular endothelial growth factor.
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Medicine (No. 1598), and it conformed to the principles of
Good Clinical Practice and the Helsinki Guidelines. This
prospective study was registered at http://www.umin.ac.jp
(UMIN000025093).
Questionnaire
The questionnaire consisted of 16 questions divided into three
categories: I, General Matters; II, Treatment Practice Pattern;
and III, Alternative Therapy (Table 1).
The questions in the General Matters included: I-1, back-
ground (1 question); I-2, changes in attitude to treatment (2
questions); and I-3, management before and after injection (2
questions). The questions in Treatment Practice Pattern
included: II-1, initial DME treatment (1 question); and II-2,
anti-VEGF treatment regimen (6 questions). The questions in
Alternative Therapy included: III-1, use of combination therapy
(2 questions); and III-2, alternative use of anti-VEGF agents (2
questions).
After the questionnaires were returned, the results were cata-
loged and analyzed. The percentage of answers to each question
was calculated and is presented as the ratio of respondents per
question. The comparisons of the demographic characteristics
of the respondents were purely descriptive. The percentages in
the charts and graphs do not add up to exactly 100%, and the
differences are due to the rounding process. Because some of
the questions consisted of multiple choices, the distribution of
the results can sometimes exceed 100%.
RESULTS
General matters
A total of 176 of 278 surveys (63.3%) were completed and
returned from 151 hospitals in 11 of the 47 prefectures of
Japan. The length of practice of the respondents ranged from 1
to 42 years: 14 had been in practice for <5 years, 27 for 5–
10 years, 60 for 11–20 years and 64 for >21 years (Figure 1a).
The analysis showed that 86.4% of the respondents believed
that the approval and accessibility of anti-VEGF treatments
changed their therapeutic strategies for treating DME, and
11.4% did not (Figure 1b). In addition, 97.2% believed that
anti-VEGF treatment was more effective than a sub-Tenon tri-
amcinolone acetonide (STTA) injection, and 2.8% did not (Fig-
ure 1c).
On the use of antibiotics, 72.7% of the respondents used
antibiotics pre- and post-injections, with a duration of 3–
7 days; 19.3% used antibiotics only post-injections; and 2.3%
used pre-injections only. In addition, 2.8% did not use any
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Figure 1 | Background and changes in attitude. (a) Practice years are shown. (b) The question on whether anti-vascular endothelial growth factor
treatment changed the therapeutic strategies for diabetic macular edema. (c) The question of whether anti-vascular endothelial growth factor
therapy is superior to sub-Tenon triamcinolone acetonide injection.
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antibiotics during the treatment period, and 2.8% used antibi-
otics only on the day of the injection (Figure 2a).
The post-injection examination protocols were: 64.2% exam-
ined their patients on the day after the injections, 11.9% at
1 week and 3.4% at 2 days. Additionally, 16.5% of the respon-
dents examined their patients at 1 month after the injections
(Figure 2b).
Treatment practice pattern
The answers for the initial therapy of DME (multiple answers)
were: 81.2% used anti-VEGF treatment, 52.8% used STTA,
49.4% used focal-PC, 9.7% used grid-PC, 9.1% used vitrectomy
and 7.4% used IVTA.
The time when anti-VEGF agents were used for the ﬁrst
time: 42.5% used it as the ﬁrst choice, 40.3% used it when
other therapies did not reduce the DME, 13.3% used it at the
request of the patients and 3.9% used it on other occasions.
The factors that were used to begin the initial therapeutic
intervention were: 44.3% used the visual acuity, 30.7% used the
optical coherence tomography ﬁndings, and 22.2% used the
patients’ complaints (Figure 3a).
The number of injections used during the loading phase was:
a single injection by 53.4% of the respondents, two consecutive
monthly injections by 8%, three consecutive monthly injections
by 26.1%, ﬁve consecutive monthly injections by 2.8%, monthly
injections by 1.7%, bimonthly injections by 1.7% and monthly
injections until an improvement of the DME was detected in
6.2% of the respondents. For all respondents, 46.6% preferred
multiple injections (Figure 3b).
During the maintenance phase after a successful loading
phase, 75.0% of the respondent used a pro re nata (PRN) regi-
men, 13.6% used the treat and extend regimen, 2.8% used
bimonthly injections, 1.1% preferred monthly injections and
7.4% did not use any additional injections (Figure 3c).
The maximum number of anti-VEGF injections used before
incorporating other therapy was three injections by 37.0% of
the respondents, two injections by 18.2%, one injection by
5.5%, four injections by 3.9% and ﬁve injections by 3.9%.
Finally, 63.0% of the respondents preferred two to ﬁve injec-
tions. A total of 30.9% of the respondents did not answer the
question on the maximum number of injections (Figure 4a).
The results to the question on whether to continue with the
anti-VEGF therapy in both responders and non-responders
showed that 85.8% of the respondents believed that the ﬁnan-
cial cost was an important factor, and 23.9% believed that the
frequency of the injections was an important factor (Figure 4b).
Other factors included probability of intraocular infection
(10.8%), general complications (6.8%) and other ocular compli-
cations; for example, 2.8% for lens damage and 2.3% for
intraocular pressure elevation.
Alternative therapy
On the question of combining other therapies with the anti-
VEGF injections, 68.2% of the respondents preferred panretinal
PC, 56.8% preferred focal PC and 50.0% preferred STTA.
Other answers included IVTA (8.0%), grid PC (5.1%), vitrec-
tomy (1.7%) and no additional treatment required (5.7%; Fig-
ure 5a).
There was one question on the safety of using intravitreal
injections of the anti-VEGF agents to treat the DME: 72.7%
believed that a prior cerebral infarction was a contraindication,
and 51.7% believed that a prior myocardial infarction was also
a contraindication. Other contraindications were cerebral hem-
orrhage (41.5%), concurrent pregnancy (22.2%), thrombotic dis-
eases (10.8%), heart disease (9.7%) and hypertension (1.7%). In
contrast, 10.8% did not mention anything about the history of
patients as a determiner of using anti-VEGF therapy (Fig-
ure 5b)
For the question about the preference of ranibizumab or
aﬂibercept, 39.8% of the respondents used them as appropriate
(Figure 5c). Among these, we also asked how the respondents
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Figure 2 | Management before and after injection. (a) The question on
how the topical antibiotics were used. Choices of answer were: only
the day of injection, both pre- and post-injection, only pre-injection,
only post-injection and none. (b) The question about the timing of
initial examination was also asked. Choices of answer were: the day
after the injection, 2 days after the injection, 1 week after the injection,
1 month after the injection and other.
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selected which was used. Of the respondents, 68.3% reported
that the general condition of the eye and patient were the fac-
tors, 19.0% replied that the visual acuity or optical coherence
tomography ﬁndings were the factors, 9.5% replied the age and
3.2% replied with other reasons.
DISCUSSION
The present ﬁndings show the methods used to treat DME by
176 ophthalmologists throughout Japan. Multiple factors, includ-
ing the physicians’ and patients’ background, inﬂuenced the
practice pattern that can cause differences in the ﬁndings from
those of RCTs. The present results reﬂect the current clinical
protocols for treatment protocols for DME in Japan, and the
results become the ﬁrst step to translating the real-world results
to the general clinical protocols for the treatment of DME.
In this survey, 176 of 278 ophthalmologists (63.3%)
responded to a 16-item questionnaire. Thus, the present results
should be a better representation than that of similar surveys in
Canada (55.4% of 61 ophthalmologists requested)12 or France
(52% of 95 ophthalmologists requested)13. The total number of
members of the Japan Retina and Vitreous Society, who are
retinal specialists, was 3,091 in 2017. We sent questionnaires to
278 specialists from 11 of 47 prefectures who participated in J-
CREST. Thus, 9% of all retinal specialists in Japan participated.
When we consider such a questionnaire-based survey from a
population of 3,000, an adequate number of participants was
estimated to be 100 (margin of error 10%) to 350 (margin of
error 5%)14. Because not all retinal specialists treat DME regu-
larly, we can conclude that the number of participants for the
present study was statistically adequate.
We asked some general questions. STTA is frequently used
for DME treatment in Japan because of its ease of use, low cost
and potentially fewer complications compared with IVTA.
However, the effectiveness of STTA is limited to only some
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Patient's complaint
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Figure 3 | Anti-vascular endothelial growth factor treatment practice pattern. (a) The question (multiple choice) was about the most important
assessment indicator for initial therapeutic intervention. The choices of answer were: visual acuity, optical coherence tomography (OCT) findings,
compliance and other. (b) The question about the initial injection numbers in the loading phase. The choices of answer were: one, two, three or
five injections, or monthly, bimonthly or until improvement. (c) The question about additional injections after an effective loading phase
(maintenance phase). The choices of answer were: monthly injection, bimonthly injection, pro re nata regimen (PRN) injection, treat and extend
regimen (TAE) injection, monthly injection until stabilization, no additional injections or other.
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DME patients, and it is often necessary to switch to anti-VEGF
treatment. This trend changed after 2006, because the effective-
ness of bevacizumab was reported15 and ranibizumab was
approved in 2014 in Japan. In fact, the present results showed
that most of the respondents reported that anti-VEGF treat-
ment changed their therapeutic strategies for managing DME
(86.4%). However, there was an opposite answer from 11.4% of
the responders. Although the results of DRCR.net Protocol-I
showed the effectiveness of anti-VEGF treatment, it is not effec-
tive for all eyes with DME, and just 60% of the eyes had their
CRT reduced to <250 lm even with continuous anti-VEGF
treatment4. Other therapies were not necessarily ineffective for
some cases; STTA is reported to be effective for some patients
when combined with focal PC16. The present results and these
reports emphasized the difﬁculty of managing DME effectively.
We also questioned the participants about the use of antibi-
otics. The guidelines from the USA have stated that pre- and
postoperative antibiotics had no signiﬁcant effects on the com-
plications of intravitreal injections17. However, the guidelines
from the Japanese Retina and Vitreous Society show that the
use of antibiotics and examinations during and after intravitreal
injections were left to the ophthalmologists’ discretion18. The
prescribing information for the use of aﬂibercept and ranibizu-
mab from the Japanese manufacturers states that the use of
antibiotics during therapy was recommended. From these state-
ments in Japan, most of the participants of our survey chose to
use antibiotics pre- and post-injection of the anti-VEGF agent.
In addition, the Japanese guideline states that there is no ﬁxed
time for the examinations after treatment, and state that they
should examine patients only when some abnormal conditions
are present. In our survey, 64.2% of the respondents examined
their patients on the day after the anti-VEGF injection. The
present results showed a compliance with the Japanese guideli-
nes on the examination and prescribing protocols. However,
because we carried out this survey in various prefectures,
including urban and rural areas, the ease of access to the exam-
ination venues was most likely different, which may might
affected the answers.
Our survey showed that 63.0% of the ophthalmologists used
more than one injection of the anti-VEGF agents as the maxi-
mum number, and most frequently used three injections
(37.0%). However, it is still not clear how many injections dur-
ing the loading phase are best for DME treatment. From RCTs,
monthly injection was most frequently carried out in the Rani-
bizumab Injection in Subjects With Clinically Signiﬁcant Macu-
lar Edema With Center Involvement Secondary to Diabetes
Mellitus (RISE) and A Study of Ranibizumab Injection in Sub-
jects With Clinically Signiﬁcant Macular Edema With Center
Involvement Secondary to Diabetes Mellitus (RIDE) studies19,
and most of the other RCT protocols stated multiple loading
injections; three initial consecutive injections in the Safety and
Efﬁcacy of Ranibizumab in Diabetic Macular Edema With Cen-
ter Involvement (RESOLVE)20 and Ranibizumab Monotherapy
or Combined with Laser versus Laser Monotherapy for Diabetic
Macular Edema (RESTORE) Studies21, four initial consecutive
injections in the DRCR.net Protocol-I3, ﬁve initial consecutive
injections in the Intravitreal Aﬂibercept Injection in Vision
Impairment due to DME (VIVID-DME) and Study of Intravit-
real Aﬂibercept Injection in Patients with DME (VISTA-DME)
study22, and monthly injections until stabilization in the
DRCR.net protocol-T23. The results from these RCT studies
showed that these loading injections were sufﬁcient. In addition,
subgroup analysis from the DRCR.net protocol-I showed that
eyes with suboptimal early vision response after an initial three
consecutive injections had poorer long-term (3 years) visual
outcomes than eyes with pronounced early responses. These
results show the importance of the initial three consecutive
injections, and also that anti-VEGF treatment is not necessarily
appropriate for all cases. From this, it can be inferred that the
initial consecutive injections are important to rule out the non-
responders24. In addition, different from the RCTs, there were
differences in the demographics of the patients, including their
insurance plans. It is still important to establish adequate load-
ing injection numbers when considering both the results of the
RCTs and real-world practices. Although a meta-analysis of 21
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Figure 4 | Continuous injections and problems. (a) The question about
the maximum number of anti-vascular endothelial growth factor
injections before using other therapies. The choices of answers were:
once, twice, three times, four times, five times, not defined and other.
(b) The question about important problems of anti-vascular endothelial
growth factor therapy (multiple answers). The choices of answer were:
financial, multiple injections, infection, general complications, lens
damage, intraocular pressure (IOP) elevation and other.
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randomized cohort studies25 and the results of 10 RCTs26
reported that the frequency of related Antiplatelet Trialists’ Col-
laborations events was not so high, the prescribing information
for allibercept and ranibizumab did mention concern about
thromboembolic events (LucentisTM prescribing information
from Genentec, https://www.gene.com/patients/medicines/lucen
tis). Some clinical studies also reported that the concentration
of the anti-VEGF drugs differed between the agents during
anti-VEGF treatment for age-related macular degeneration27–29.
This implies that there might be differences in the risk for
thromboembolic events between the two anti-VEGF agents.
Although it is still not known whether intravitreal injection of
anti-VEGF agents affected the systemic VEGF, this lack of
information creates a concern in Japanese physicians when they
carry out anti-VEGF treatments.
In Japan, two anti-VEGF agents have been approved for use
in patients with DME, and they have comparable prices. The
DRCR.net Protocol-T23 reported that there might exist different
effectiveness between these two agents. Among our respon-
dents, 39.8% used the two approved agents appropriately, and
among them, 68.3% used them according to the general com-
plications and 19.0% used them based on the differences in
their effectiveness. Alternative uses of the approved anti-VEGF
agents are effective for some patients, because each agent has a
different pharmacological aspect.
The rationale for combination therapy is that it might
improve the effectiveness of a single therapy or might reduce
the number of injections that would reduce the chances of
complications and lessen the ﬁnancial burdens. Because sus-
tained-release steroid agents have not been approved in Japan,
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Figure 5 | Alternative therapy. (a) The question about combination therapy with anti-vascular endothelial growth factor injections (multiple choice).
The choices of the answers were: panretinal photocoagulation (PC), focal photocoagulation (PC), sub-Tenon triamcinolone acetonide injection
(STTA), intravitreal triamcinolone acetonide injection (IVTA), macular grid photocoagulation (PC), vitrectomy, none or other. (b) The question
regarding safety (multiple choice). The choices of answers were: cerebral infarction, myocardial infarction, cerebral hemorrhage, potential pregnancy,
thrombotic disease, heart disease, hypertension and none. (c) The question about whether two approved anti-vascular endothelial growth factor
agents, ranibizumab and aflibercept, were used was also asked.
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the treatment patterns in Japan are different from other
countries. From our survey, just 5.7% of the respondents used
anti-VEGF monotherapy, which indicates that physicians are
aware of the difﬁculties in managing DME with only anti-
VEGF therapy. Thus, some type of combination therapy
including PC or STTA needs to be considered, although their
effectiveness has not been fully determined.
Comparing the present results with the previous surveys in
other countries, there are similar trends. From the real-world
patient data in Denmark and the USA, the frequency of use of
anti-VEGF agents is increasing, especially after governmental
approval11,30. From the European Union survey, the average
injection numbers of anti-VEGF agents were low, which might
indicate the difﬁculty of frequent injections except in RCTs31.
Ogura et al.32 reported on the clinical practice patterns of 83
retinal specialists in Japan. Similar to the present results, 76.3%
of the ophthalmologists preferred the PRN regimen, but 50.0%
responded that the treat and extend regimen was ideal.
Although the results tended to be similar to the present results,
they differed from our survey because the respondents were
mainly retinal specialists practicing at university hospitals or
general hospitals. Our survey included not only university hos-
pitals, but also small primary and private clinics. The present
results complement earlier reports, and we can determine the
Japanese general clinical treatment protocol for DME from
both types of results. However, it is necessary to carry out simi-
lar surveys frequently, because the trends also change with time,
and the introduction of new drugs and procedures.
Different from other retinal disease treated with anti-VEGF
agents; that is, age-related macular degeneration, retinal vein
occlusion and myopic choroidal neovascularization, there exist
differences between the BCVA and retinal thickness for the
treatment protocol for DME33. In our respondents, 44.3% used
anti-VEGF based on the BCVA, and 30.7% based on the optical
coherence tomography ﬁndings. These results reﬂect a unique
aspect of DME in the actual clinical practice. Second, most oph-
thalmologists prefer one-time injection in the loading phase and
PRN for the maintenance phase. Therefore, the results indicated
that the 1 + PRN regimen is preferred in Japan.
The present study had several limitations. First, the study
design was not based on clinical patient visits. Owing to the
indirect inclusions, the study could be susceptible to physicians’
bias. Second, the real-world trend from our survey does not
necessarily mean that they are the most effective treatment.
Although our results showed that the 1 + PRN regimen is
preferred, it is still unclear whether the 1 + PRN regimen is
effective. We must realize the differences between RCT and
real-world trends, and the present results are not from patient
data, but generally, retrospective studies using RWE are consid-
ered to be of less statistical and clinical value than prospective
RCT results. However, this weakness might be lessened by
using many participants34.
In conclusion, the present study showed the Japanese trend
of anti-VEGF treatment. It will be important to continue to
survey new indications of drugs to receive both high-quality
and cost-effective care from analysis of real-world trends.
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